Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis

Authors: Nicola J. Grant, Philip J. Coates, Yvonne L. Woods, Susan E. Bray, Nicholas A. Morrice, C. James Hastie, Douglas J. Lamont, Francis A. Carey, Calum Sutherland

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Cyclin-dependent protein kinase-5 (CDK5) is an unusual member of the CDK family as it is not cell cycle regulated. However many of its substrates have roles in cell growth and oncogenesis, raising the possibility that CDK5 modulation could have therapeutic benefit. In order to establish whether changes in CDK5 activity are associated with oncogenesis one could quantify phosphorylation of CDK5 targets in disease tissue in comparison to appropriate controls. However the identity of physiological and pathophysiological CDK5 substrates remains the subject of debate, making the choice of CDK5 activity biomarkers difficult.

Methods

Here we use in vitro and in cell phosphorylation assays to identify novel features of CDK5 target sequence determinants that confer enhanced CDK5 selectivity, providing means to select substrate biomarkers of CDK5 activity with more confidence. We then characterize tools for the best CDK5 substrate we identified to monitor its phosphorylation in human tissue and use these to interrogate human tumour arrays.

Results

The close proximity of Arg/Lys amino acids and a proline two residues N-terminal to the phosphorylated residue both improve recognition of the substrate by CDK5. In contrast the presence of a proline two residues C-terminal to the target residue dramatically reduces phosphorylation rate. Serine-522 of Collapsin Response Mediator-2 (CRMP2) is a validated CDK5 substrate with many of these structural criteria. We generate and characterise phosphospecific antibodies to Ser522 and show that phosphorylation appears in human tumours (lung, breast, and lymphoma) in stark contrast to surrounding non-neoplastic tissue. In lung cancer the anti-phospho-Ser522 signal is positive in squamous cell carcinoma more frequently than adenocarcinoma. Finally we demonstrate that it is a specific and unusual splice variant of CRMP2 (CRMP2A) that is phosphorylated in tumour cells.

Conclusions

For the first time this data associates altered CDK5 substrate phosphorylation with oncogenesis in some but not all tumour types, implicating altered CDK5 activity in aspects of pathogenesis. These data identify a novel oncogenic mechanism where CDK5 activation induces CRMP2A phosphorylation in the nuclei of tumour cells.
Appendix
Available only for authorised users
Literature
1.
2.
Tang D, Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K, et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem. 1995;270(45):26897–903.CrossRefPubMed
3.
4.
Tang D, Chun AC, Zhang M, Wang JH. Cyclin-dependent kinase 5 (Cdk5) activation domain of neuronal Cdk5 activator. Evidence of the existence of cyclin fold in neuronal Cdk5a activator. J Biol Chem. 1997;272(19):12318–27.CrossRefPubMed
5.
Poon RY, Lew J, Hunter T. Identification of functional domains in the neuronal Cdk5 activator protein. J Biol Chem. 1997;272(9):5703–8.CrossRefPubMed
6.
Ohshima T, Ward JM, Huh CG, Longenecker G. Veeranna, Pant HC et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A. 1996;93(20):11173–8.CrossRefPubMedPubMedCentral
7.
Gilmore EC, Ohshima T, Goffinet AM, Kulkarni AB, Herrup K. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J Neurosci. 1998;18(16):6370–7.PubMed
8.
Ohshima T, Gilmore EC, Longenecker G, Jacobowitz DM, Brady RO, Herrup K, et al. Migration defects of cdk5(−/−) neurons in the developing cerebellum is cell autonomous. J Neurosci. 1999;19(14):6017–26.PubMed
9.
Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 1997;18(1):29–42.CrossRefPubMed
10.
Kwon YT, Tsai LH. A novel disruption of cortical development in p35(−/−) mice distinct from reeler. J Comp Neurol. 1998;395(4):510–22. doi:10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4.CrossRefPubMed
11.
12.
Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci. 2001;21(17):6758–71.PubMed
13.
14.
Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem. 2000;275(22):17166–72. doi:10.​1074/​jbc.CrossRefPubMed
15.
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615–22.CrossRefPubMed
16.
17.
18.
Cole AR, Knebel A, Morrice NA, Robertson LS, Irving AJ, Connolly CN, et al. GSK-3 phosphorylation of the Alzheimers epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem. 2004;279(48):50176–80.CrossRefPubMedPubMedCentral
19.
Brown M, Jacobs T, Eickholt B, Ferrari G, Teo M, Monfries C, et al. Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci. 2004;24(41):8994–9004. doi:10.​1523/​JNEUROSCI.​3184-04.​2004.CrossRefPubMed
20.
Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, et al. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem. 2006;281(24):16591–8.CrossRefPubMedPubMedCentral
21.
Causeret F, Jacobs T, Terao M, Heath O, Hoshino M, Nikolic M. Neurabin-I is phosphorylated by Cdk5: implications for neuronal morphogenesis and cortical migration. Mol Biol Cell. 2007;18(11):4327–42.CrossRefPubMedPubMedCentral
22.
23.
24.
25.
Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402(6762):669–71.CrossRefPubMed
26.
27.
28.
Lee KY, Helbing CC, Choi KS, Johnston RN, Wang JH. Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. J Biol Chem. 1997;272(9):5622–6.CrossRefPubMed
29.
30.
Cheung ZH, Gong K, Ip NY. Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. J Neurosci. 2008;28(19):4872–7.CrossRefPubMed
31.
Zhang J, Krishnamurthy PK, Johnson GV. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem. 2002;81(2):307–13.CrossRefPubMed
32.
Fu AK, Fu WY, Ng AK, Chien WW, Ng YP, Wang JH, et al. Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. Proc Natl Acad Sci U S A. 2004;101(17):6728–33.CrossRefPubMedPubMedCentral
33.
Huang C, Rajfur Z, Yousefi N, Chen Z, Jacobson K, Ginsberg MH. Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat Cell Biol. 2009;11(5):624–30.CrossRefPubMedPubMedCentral
34.
Sandal T, Stapnes C, Kleivdal H, Hedin L, Doskeland SO. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells. J Biol Chem. 2002;277(23):20783–93. doi:10.​1074/​jbc.CrossRefPubMed
35.
36.
37.
Liu X, Li L, Chen ZJ, Lu Z, Shi Y, Zhao Y. Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women. Gynecol Endocrinol. 2010;26(2):129–34. doi:10.​3109/​0951359090321549​0.CrossRefPubMed
38.
39.
Choi HS, Lee Y, Park KH, Sung JS, Lee JE, Shin ES, et al. Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population. J Hum Genet. 2009;54(5):298–303. doi:10.​1038/​jhg.​2009.​29.CrossRefPubMed
40.
41.
Pozo K, Hillmann A, Augustyn A, Plattner F, Hai T, Singh T, et al. Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis. Oncotarget. 2015;6(14):12080–93.CrossRefPubMedPubMedCentral
42.
43.
Lindqvist J, Imanishi SY, Torvaldson E, Malinen M, Remes M, Orn F, et al. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol Biol Cell. 2015;26(11):1971–84. doi:10.​1091/​mbc.​E14-12-1634.CrossRefPubMedPubMedCentral
44.
Upadhyay AK, Ajay AK, Singh S, Bhat MK. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets. 2008;8(8):741–52.CrossRefPubMed
45.
46.
Patel S, Lochhead PA, Rena G, Fumagalli S, Pende M, Kozma S, et al. Insulin regulation of IGF-binding protein-1 gene expression is dependent on mammalian target of rapamycin (mTOR), but independent of S6K activity. J Biol Chem. 2002;277(12):9889–95.CrossRefPubMed
47.
Petsalaki E, Dandoulaki M, Morrice N, Zachos G. Chk1 protects against chromatin bridges by constitutively phosphorylating BLM serine 502 to inhibit BLM degradation. J Cell Sci. 2014;127(18):3902–8. doi:10.​1242/​Jcs.​155176.CrossRefPubMed
48.
Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, Cochet C, et al. A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol. 1996;16(11):6486–93.CrossRefPubMedPubMedCentral
49.
Hanger DP, Seereeram A, Noble W. Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Expert Rev Neurother. 2009;9(11):1647–66.CrossRefPubMed
50.
Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, Yu CJ, et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst. 2001;93(18):1392–400.CrossRefPubMed
51.
Shih JY, Lee YC, Yang SC, Hong TM, Huang CY, Yang PC. Collapsin response mediator protein-1: a novel invasion-suppressor gene. Clin Exp Metastasis. 2003;20(1):69–76.CrossRefPubMed
52.
Oliemuller E, Pelaez R, Garasa S, Pajares MJ, Agorreta J, Pio R, et al. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC. Int J Cancer. 2013;132(9):1986–95. doi:10.​1002/​ijc.​27881.CrossRefPubMed
53.
54.
Vincent EE, Elder DJ, Linda O’F, Pardo OE, Dzien P, Phillips L, et al. Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation. PLoS One. 2014;9(12):e114725. doi:10.1371/journal.pone.0114725 PONE-D-14-28880.CrossRefPubMedPubMedCentral
55.
Vincent P, Collette Y, Marignier R, Vuaillat C, Rogemond V, Davoust N, et al. A role for the neuronal protein collapsin response mediator protein 2 in T lymphocyte polarization and migration. J Immunol. 2005;175(11):7650–60.CrossRefPubMed
56.
Vuaillat C, Varrin-Doyer M, Bernard A, Sagardoy I, Cavagna S, Chounlamountri I, et al. High CRMP2 expression in peripheral T lymphocytes is associated with recruitment to the brain during virus-induced neuroinflammation. J Neuroimmunol. 2008;193(1–2):38–51. doi:10.​1016/​j.​jneuroim.​2007.​09.​033.CrossRefPubMed
57.
Watanabe Y. Experimental model of human lung cancer, Part I. Establishment and characterization of new tissue culture cell lines from human squamous cell carcinoma and adenocarcinoma of the lung. Okayama Igakkai zasshi. 1985;97:691–775.
58.
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51(5):1417–23.PubMed
59.
Banks-Schlegel SP, Gazdar AF, Harris CC. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res. 1985;45(3):1187–97.PubMed
60.
Yuasa-Kawada J, Suzuki R, Kano F, Ohkawara T, Murata M, Noda M. Axonal morphogenesis controlled by antagonistic roles of two CRMP subtypes in microtubule organization. Eur J Neurosci. 2003;17(11):2329–43.CrossRefPubMed
61.
62.
63.
Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, et al. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010;29(32):4555–66. doi:10.​1038/​onc.​2010.​213.CrossRefPubMed
Metadata
Title
Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis
Authors
Nicola J. Grant
Philip J. Coates
Yvonne L. Woods
Susan E. Bray
Nicholas A. Morrice
C. James Hastie
Douglas J. Lamont
Francis A. Carey
Calum Sutherland
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1691-1

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

The end of the decline in cervical cancer mortality in Spain: trends across the period 1981–2012

Research article

Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection

Research article

Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin

Research article

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome

Research article

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma

Research article

Non-participation in breast cancer screening for women with chronic diseases and multimorbidity: a population-based cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits